Qiagen NV, Venlo, the Netherlands (NASDAQ: QGEN / XETRA: QIA)
A leading global provider of sample and assay technologies used to transform biological materials into molecular information, marketing more than 500 products around the world, selling both consumable kits and automation systems.
Evaluate market entry into Chinese market through the acquisition of various companies and assets (‘string-of-pearls’ acquisition strategy).
Tianwei Times, a leading developer, manufacturer and supplier of nucleic acid sample preparation consumables for pre-analytic testing with a sizeable network of established customers of leading research and academic institutions in China.
Qiagen NV acquired asset and technology portfolio of Tianwei Times based on an up-front payment and a revenue earn-out. Financial terms were not disclosed.
Acted as a consultant to the Board of Directors and senior management
- Compiled analysis of Chinese life science’s market.
- Screened and analysed more than 20 potential acquisition targets to develop ‘string-of-pearls’ acquisition strategy encompassing three targets.
- Identified Tianwei Times as initial acquisition target.
- Assisted internal business development team in negotiations and execution of the transaction as the first ‘pearl’ on the string.
N.B. Consulting services performed prior to the formation of CATALYSIS CAPITAL PARTNERS LTD. and authorisation and regulation by FCA UK
